Despite the technological and pharmacological advancements in the last 30 years, morbidity and mortality of dialysis patients are still astonishingly high. Today, convective treatments, such as high-flux haemodialysis (hf-HD) and haemodiafiltration (HDF), are established techniques; the online production of fresh pure dialysate has provided clinical and economic advantages. Nevertheless, the actual benefits of HDF, even with highconvective-volume treatments, are still debatable. Three recent, randomized controlled trials compared survival outcomes in prevalent patients receiving conventional HD or post-dilution HDF and reported conflicting results. The meta-analyses of the published trials were ultimately incapable of providing a clear and definitive answer on the possible beneficial effects of choosing one treatment over the other. All-cause mortality, anaemia, phosphate control and clearance of small molecules seemed to be unaffected by the treatment modality. On the other hand, cardiovascular mortality, intradialytic vascular stability and the clearance of protein-bound molecules fared better in patients treated with HDF. These results were not consistent between the studies. Thus, there is still no conclusive answer to the question that nephrologists would like to have answered: 'Which is the best treatment for my patient?' In the age of evidence-based medicine, we need strong data to support the superiority of a treatment in comparison with another, although theoretically plausible. There is the need for a well-designed clinical trial comparing outcomes for patients randomly assigned to high-or moderate-convection-volume HDF versus hf-HD to clearly prove the clinical superiority of HDF, including the effect of different infusion volumes.
I N T R O D U C T I O N
The population of patients with end-stage renal disease (ESRD) is increasing yearly [1] . It is estimated that >1 million patients with ESRD can survive, thanks to different forms of renal replacement therapies (RRTs). Dialysis can act as a bridge towards transplant or a life-long treatment. Given the shortage of organs and that a large proportion of ESRD patients are old and frail, transplantation can be offered only to a small subset of patients. The remaining population needs dialysis for years, and eventually tend to develop dialysis-related comorbidities.
Haemodialysis (HD) modalities can be subdivided into three main categories: low-flux haemodialysis (lf-HD), high-flux haemodialysis (hf-HD) and haemodiafiltration (HDF).
lf-HD relies on diffusion to restore the intracellular and extracellular fluid environment using a membrane with small pores and low ultrafiltration coefficient. In addition to the concentration gradient, the rate of diffusion of the molecules is inversely proportional to the square root of their molecular weight. The mortality rate of patients treated with lf-HD is still 15-25% per year and morbidity is very relevant, thus highly impacting the quality of life [2] .
More than 30 years ago, the hypothesis that the high morbidity and mortality rates of lf-HD were associated with inadequate removal of middle solute molecules led to the implementation of hf-HD [3] .
hf-HD utilizes membranes with bigger pores and high ultrafiltration coefficient, and it can remove solutes of higher molecular weight. Moreover, the biocompatibility of high-flux membranes reduces chronic inflammation and oxidative stress [4] , which is strongly associated with malnutrition and atherosclerosis [5] .
The Membrane Permeability Outcome (MPO) Study [6] found, only in patients with serum albumin <4 g/dL, a significant 37% relative risk (RR) reduction of mortality using highflux instead of the low-flux membrane.
In the light of these findings, the European Renal Best Practice (ERBP) Advisory Board recommended that hf-HD should be used in the case of high-risk patients (like the lowalbumin group of the MPO study) and upgraded the strength of the guidance to a level 1A (strong recommendation, based on high-quality evidence). Considering the substantial improvement in b 2 -microglobulin in the hf-HD group, the ERBP Advisory Board suggested that high-flux membranes should be recommended even in low-risk patients (level 2b: weak recommendation, low-quality evidence) [7] .
The rationale for using HDF is based on simultaneous diffusive and convective transport, which combines the beneficial effects of diffusive HD with the possible advantages of large convective volumes. During HDF the convective clearance for a given solute depends on the total ultrafiltered volume and the solute sieving coefficient of the membrane.
After >40 years since the first clinical experience, there are still many open questions around this dialysis technique. In particular, the available evidence is still considered not strong enough to demonstrate that HDF provides better outcomes compared with HD. It is also significant that the guidelines recommending ol-HDF were not upgraded, as was the case of hf-HD. What do we need to confidently affirm that online HDF should be considered the optimal treatment?
Small molecules
Small molecules (<500 Da) are effectively cleared by diffusion. Clinical studies indicate that the clearance of urea is only slightly higher with ol-HDF than with HD [8] [9] [10] [11] .
Phosphate is a peculiar type of small molecule, since its removal from the bloodstream is hampered by complex exchanges and sequestrations in other compartments. Hyperphosphataemia has been associated with increased risk of all-cause mortality, including the cardiovascular risk [12] . Adequate control of hyperphosphataemia is rarely achieved even when dialysis is adequate according to urea Kt/V values suggested by the present guidelines. The available data on phosphate removal with ol-HDF are contrasting and inconclusive. Compared with standard HD, they showed decreased [13] [14] [15] or equivalent phosphate levels [16] and phosphate mass removal [11, 17] . The effect of the dose of dialysis (Kt/V and the t is a key factor in this case) should always be taken into consideration when comparing different techniques. This is what the study of Cornelis et al. [11] did, with a direct dialysate quantification to assess uraemic toxin removal. No difference between ol-HDF and hf-HD was found in phosphate removal, with time being the only important factor making a difference.
In conclusion, according to the results of Cornelis et al. [11] , HDF should not be selected just to increase small moleculesincluding phosphate removal.
Middle molecules
Middle molecules consist mostly of peptides and lowmolecular-weight proteins; some of them are toxic. b 2 -microglobulin is considered a representative of this class of molecules, since it is the major compound found in the amyloid fibrils of carpal deposits. Hence, its removal is desirable [18] . More importantly, its serum levels have been associated with mortality [19] , even though this association was not reported in recent randomized trials.
There is a general agreement that hf-HD and ol-HDF are able to decrease the plasma levels of b 2 -microglobulin compared with lf-HD [8, 20, 21] . However, in a prospective, randomized, multicentre trial, Locatelli et al. [20] found a similar significant decrease in pre-dialysis plasma b 2 -microglobulin levels between hf-HD and low-convection HDF in comparison with lf-HD. In another prospective, randomized trial, Ward et al. [21] confirmed a similar decrease of pre-dialysis levels over time, despite an apparent difference in the removal of b 2 -microglobulin, as indicated by a significantly higher pre-to post-treatment reduction in plasma concentrations in low-convection HDF. A substantial rebound in post-treatment plasma b 2 -microglobulin concentrations has been reported [22] ; the area under the curve of b 2 -microglobulin plasma concentration should be considered as a better indicator of the exposure to its potential toxicity. A large, observational study compared convective with diffusive treatments [23] and reported a 42% lower RR for surgical intervention for carpal tunnel syndrome, very similar to the associated RR in the Japanese Registry [24] , which compared conventional with high-flux membrane.
Interestingly, Cornelis et al. [11] showed a significantly improved removal of fibroblast growth factor 23 in HDF compared with HD.
In a recent meta-analysis, Roumelioti et al. [25] found that HDF obtained greater b 2 -microglobulin reduction ratios relative to hf-HD; the adsorption properties of membrane material proved to be an important determinant of b 2 -microglobulin clearance.
In conclusion, HDF improves the removal of middle molecules, and, in addition, an increase in convection should further increase their removal. However, there is no data clearly demonstrating that a better removal of b 2 -microglobulin and other middle molecules directly translate into better hard clinical outcomes.
Protein-bound molecules
Some uraemic retention solutes bind to plasma proteins, particularly to serum albumin. p-Cresol and indoxyl sulphate are the two leading protein-bound molecules that are possibly implicated in endothelial dysfunction [26] ; increasing their removal is highly desirable. Accordingly, studies on HDF found that low p-cresol concentrations were associated with a significant lower mortality in dialysis patients [27] . However, a recent analysis of the HEMO study seems to put some shadow on the clinical relevance of p-cresol and indoxyl sulphate [28] .
Other authors found that the elimination of the unbound fraction of these solutes was higher during HDF and with greater filtration volumes [29, 30] , suggesting a potential benefit of HDF in this respect.
In conclusion, our understating of the role and kinetics of protein-bound uraemic retention solutes is still insufficient and there is quite a substantial amount of work to be done in this regard.
C A R D I O V A S C U L A R S T A B I L I T Y A N D H Y P E R T E N S I O N
Cardiovascular instability is the most frequent clinical problem in HD patients. The importance of preventing intradialytic hypotension is mainly related to the need to prevent the stunning of the myocardium and of other vital organs (including the brain and the gut) and to reach the patient's dry body weight. This allows a better control of hypertension, which is mainly dependent on fluid overload in this patient population.
There is debate in the literature whether HDF can improve cardiovascular stability.
Some studies suggested a beneficial effect of HDF compared with HD in this regard [31] [32] [33] [34] [35] . Data from four meta-analyses were also concordant about a positive effect of convective techniques in improving cardiovascular stability [36] [37] [38] [39] .
Other studies were unable to demonstrate the beneficial effect of HDF on cardiovascular stability [11] , possibly because the incidence of intradialytic hypotension was much lower than expected in the population as a whole [20] . A recent French study [40] also failed to demonstrate a positive effect of HDF at primary analysis and in numerous post hoc analyses. The only result of this study that reached statistical significance was the higher number of sessions with asymptomatic hypotension.
Surprisingly, a short-term study found that episodes of symptomatic intradialytic hypotension were even higher in the HDF group [41] . Moreover, the post-dialysis recovery time did not differ between HDF and HD, although the proportion of patients reporting immediate recovery was significantly higher when receiving HDF. This parameter is emerging as an overlooked measure of dialysis tolerability and is associated with increased mortality [42] .
Finally, using functional magnetic resonance imaging, Buchanan et al. [43] found no difference in cardiac wall motion abnormalities for HDF versus HD. A possible interpretation of these results could be related to the same blood pressure behaviour in the two modalities.
There are two possible explanations of the possible beneficial effect of HDF on cardiovascular stability. Since the dialysate and the reinfusate have the same sodium concentration, there is a small retention of sodium during HDF due to the Donnan effect, partially balanced by the diffusive mechanism, even with larger substitution volume, due to the increased gradient between the patient's sodium plasma water and the dialysate.
Anyway, the potential beneficial effect of a reduction of intradialytic symptomatic hypotension with HDF should be balanced with a possible increase in pre-dialysis systolic blood pressure, possibly related to sodium retention [34] that could lead to increased interdialytic weight gain.
Three decades ago, Maggiore et al. [44] [45] [46] and Mahida et al. [47] identified blood cooling as the main blood pressure stabilizer. During ol-HDF there is possibly an enhanced energy loss within the extracorporeal system, despite identical temperature settings for dialysate and substitution fluids. The intradialytic temperature could be adjusted in HD in order to match the thermal balance of HDF and thus obtain the same improvement in intradialytic cardiovascular stability [48] . In conclusion, as Cornelis et al. [11] clearly stated, in acute dialysis settings, treatment time, and not modality, is the determinant for the haemodynamic response.
A N A E M I A M A N A G E M E N T
Anaemia is a common complication of ESRD, affecting the majority of patients on dialysis. Convective treatments can remove more easily middle molecular weight inhibitors of erythropoiesis. Accordingly, an improvement in anaemia control had been observed after switching from standard lf-HD to HD when using highly permeable and biocompatible membranes in several small and uncontrolled studies [49] [50] [51] , and in a small randomized study [52] . However, some studies showed that the use of ultrapure dialysis fluid resulted in for increased haemoglobin (Hb) levels and decreased need of erythropoiesis-stimulating agents (ESAs) [53, 54] . In this respect, it should be mentioned that a beneficial effect of HDF on anaemia control was found when ultrapure dialysis fluid was not used in the control group [55] .
The Italian Cooperative Dialysis Study compared biocompatible and traditional dialysers, as well as convective and diffuse treatment modalities [20] . A secondary analysis showed a significant increase in Hb levels in patients on hf-HD and HDF compared with those on lf-HD, but did not find any difference when these groups were analysed separately. One large, observational, cohort study from the Japanese Phase II DOPPS (Dialysis Outcomes and Practice Patterns Study) [56] , as well as two randomized controlled trials [57, 58] failed to demonstrate an effect of hf-HD on anaemia. A pre-specified secondary analysis of a multicentre, open-label, randomized clinical trial [34] found that, in comparison with lf-HD, neither haemofiltration (HF) nor HDF significantly improved Hb levels or decreased ESA requirements.
The effect of online HDF on ESA resistance and iron parameters was a pre-specified secondary endpoint of the randomized Convective Transport Study (CONTRAST) [59] . After 12 months, the erythropoietin resistance index (ERI) was not different between patients treated with HDF or HD. Even in the highest tertile of convection volume (>22 L), which was associated with a beneficial effect of HDF on mortality, there was no effect on ESA resistance. In these subjects, only a trend towards a lower transferrin saturation ratio and lower ferritin levels was found, despite slightly more iron supplementation.
In the Turkish Online Haemodiafiltration Study [60] , the HDF and the hf-HD groups had similar clinical outcome; despite this, the mean ESA dosage was significantly lower in the HDF group than in the hf-HD patients.
Conversely, the On-Line Haemodiafiltration Survival Study (ESHOL) [35] showed a significant reduction in all-cause mortality with HDF, but Hb levels and ESA dose did not differ compared with hf-HD.
A meta-analysis of 65 studies compared convective therapies (including hf-HD, HF and HDF) with lf-HD: in patients treated with convective or hybrid therapies, ESA dose needs and iron parameters did not improve significantly compared to lf-HD [38] .
The REDERT (role of HDF on ERI) study was designed to test the effect of high-volume (>20 L/session) HDF on ERI and hepcidin levels [61] . In this two-arm, multicentre, crossover study, 40 stable HD patients were randomized to either ol-HDF or standard lf-HD. Interestingly, Hb levels remained stable, while the total amount of ESAs administered during HD was considerably higher. Hepcidin levels were lower in HDF compared with standard HD.
In their propensity-score-matched long-term trial, Marcelli et al. [62] reported that a clear difference between HD-and HDF-treated patients could only be found for patients with high baseline ERI and assigned to intravenous ESA.
Of note, in a multivariate analysis, Locatelli et al. [63] found that the participating centre was the most significant predictor of Hb levels and ESA resistance, suggesting a large degree of heterogeneity among individual centres in treating anaemia.
Overall, the results of clinical studies on this topic are conflicting and differ substantially with respect to the treatment protocol (including dialysers and use of ultrapure dialysis fluid), control group and the treatment dose (i.e. applied convection volume). Hence, when looking exclusively at anaemia control, no single treatment modality seems to be really preferable over another, given an equivalent dialysis fluid quality.
S U R V I V A L
In 2006, the DOPPS analysed 2165 patients from five European countries, who had been receiving HDF versus HD from 1998 to 2001, and stratified them into four groups: lf-and hf-HD (respectively 63% and 25.2% of all the patients), and low-and high-efficiency HDF (respectively 7.2% and 4.5% of all the patients) [64] . The patients receiving high-efficiency HDF had a significant 35% lower RR of mortality than those receiving lf-HD. On the other hand, the patients receiving low-efficiency HDF had a non-significant 7% lower RR of mortality compared with those receiving lf-HD. These results are apparently impressive. However, the lf-HD patients had a mean follow-up of <3 months compared with the other groups, who had a followup of almost 2 years. Moreover, the number of patients treated with high-efficiency HDF was quite small; hence, a selection bias by treatment indication could not be ruled out, limiting the generalizability of these findings.
The findings of the DOPPS study [64] were a strong stimulus for planning five randomized trials [34, 35, 40, 59, 60] .
Mortality was not a primary outcome in the study by Locatelli et al. [34] . Anyway, they reported no differences for dropouts caused by death or kidney transplantation. This is in line with the findings of the studies by Wizemann et al. [65] , Bolasco et al. [66] and Schiffl [67] . A common drawback of most studies published before a clear definition of HDF [68] is that techniques with low-convective-volume (e.g. acetate-free biofiltration) or only convective (e.g. HF) were grouped together with HDF as 'convective treatments'.
In the CONTRAST study [59] , after a mean follow-up of 3.03 years, the incidence of all-cause mortality was not affected by treatment assignment, although a subgroup analysis suggested a benefit on all-cause mortality among patients treated with high-convective volumes (>20 L/treatment) (HR 0.66; P ¼ 0.03).
In the TURKISH HDF Study [60] , the composite endpoint of death from any cause and non-fatal cardiovascular events was not different between post-dilution ol-HDF and hf-HD. However, in a post hoc analysis, HDF treatment with substitution volume >17.4 L was associated with a 46% RR reduction of overall mortality (P ¼ 0.02) and a 71% RR reduction of cardiovascular mortality (P ¼ 0.003) compared with HD.
Interestingly, in a post hoc analysis of these two studies, the delivered substitution volume during the entire HDF session (17-20 L/session), which is a surrogate of the convective dialysis dose, was identified as an independent and critical factor associated with improved survival. This is in agreement with the findings of the DOPPS study [64] .
ESHOL is the only randomized study that showed a significant advantage of ol-HDF in all-cause mortality, stroke mortality and infection-related mortality [35] . In line with the findings of the post hoc analyses of the previous two studies, the ESHOL trial is also the one that achieved the highest convection volumes (22.9-23.9 L/HD session). However, the solidity of the data depends on the quality of randomization. Unfortunately, in the ESHOL trial, the patients randomized to ol-HDF were younger, male in a higher percentage, diabetic in a lower percentage, having more artero-venous fistulas and fewer central vein catheters and overall had a lower comorbidity index [69] . Moreover post-randomization exclusion of the patients randomized to HDF and unable to reach a reinfusion volume >18 L was foreseen by the protocol, thus creating an important bias.
Another critical point while interpreting the findings of these studies is that the majority of the patients did not reach the target exchange volume [35, 59, 60] . The exchange volume can be influenced by the flow of the vascular access: the patients obtaining higher exchange volume are then more likely to have better vessels. This may imply a lower burden of cardiovascular disease and possibly a better survival rate. Thus, a selection bias could be a possible explanation for the results of the secondary analyses of these trials, since the possibility that larger reinfusion volumes could be easier in patients with better vascular access cannot be ruled out. It is also possible that the different results of the ESHOL and CONTRAST studies were partially influenced by a different transplantation rate [70] , thus adding further difficulties in the interpretation of results.
Recently, Morena et al. [40] performed a randomized clinical trial, which focused on treatment tolerance in elderly patients. They did not find a significant difference in either all-cause or cardiovascular mortality between HD and HDF, or between HDF patients receiving convective volume <20 or >20 L. This trial suggests that in older dialysis patients, the benefits of HDF may be modest. Other observational studies reported a better survival associated with the use of HDF [71] [72] [73] [74] [75] . In particular, the Romanian EUCLID (European Clinical Dialysis) database [72] showed a low hazard ratio (HR) favouring prevalent patients treated with HDF [adjusted HR ¼ 0.58, confidence interval (CI) 0.36À0.93]; compared with standard HD, the HR for survival was even more impressive in incident patients (adjusted HR ¼ 0.24, CI 0.13-0.46).
In Figure 1 , we present a graphical summary of the all-cause mortality risk ratios of the presented randomized trials. Table 1 summarizes their main outcomes. Figure 2 displays a summary of all-cause mortality risk ratios for the considered observational studies.
A number of meta-analyses were published about the possible benefits of HDF on patient survival.
Susantitaphong et al. [38] found a non-significant decrease in all-cause mortality (RR 0.88; 95% CI 0.76-1.02) and all-cause hospitalization (RR 0.91; 95% CI 0.82-1.01), but a significant decrease in cardiovascular mortality (RR 0.84; 95% CI 0.71-0.98) and treatment-related hypotension (RR 0.55; 95% CI 0.35-0.87).
Nistor et al. [37] did not show significant advantages of convective techniques in comparison with the prevalent diffusive ones, although a 25% significant reduction of cardiovascular mortality was seen in patients treated with convective techniques. No significant advantages for non-fatal cardiovascular events and hospital admission were found.
Wang et al. [36] also did not find a significant difference in the overall mortality and cardiovascular events between the patients treated with HF and HDF and lf-and hf-HD, although a numeric HR reduction of 15% and of 17%, respectively, was found.
Peters et al. [76] conducted a pooled, individual, patient analysis of randomized controlled trials, in order to provide more reliable evidence for the effects of HDF on mortality outcomes. Individual Patients Data analyses can bring substantial improvements to the quantity and quality of data and provide more detailed and robust results than aggregate meta-analyses. It is also important to recognize that the quality of individual patient's data depends on the quality of the original studies. A meta-analysis of individual patient's data from a set of trials with many potential sources of bias, even if sorted out as much as possible, is as deficient as the original trials. After a median follow-up of 2.5 years, 769 of the 2793 participants had died (292 cardiovascular deaths). ol-HDF significantly reduced the RR of all-cause mortality by 14% and of cardiovascular mortality by 23%. There was no evidence of differentiated effects in the subgroups, which suggests an uniform positive effect independent of clinical conditions. In a secondary analysis, the largest survival benefit was observed in the patients receiving the highest delivered convection volume (>23 L per 1.73 m 2 body surface area per session) with a multivariableadjusted HR of 0.78 for all-cause mortality and 0.69 for cardiovascular disease mortality.
According to a cause-specific meta-analysis of the same data set of Peters et al., performed by Nubé et al. [77] , to prevent a death from any cause or from cardiovascular reasons, 32 and 75 patients, respectively, have to be treated for 1 year. Table 2 shows the main outcomes of these meta-analyses. Canaud et al. [78] performed a retrospective, international study of 2293 incident HD patients with a minimum of 2 years of follow-up. They found that the adjusted survival benefit of ol-HDF increases at $55 L/week of convective volume (i.e. 18.3 L/session) and remained increased up to $75 L/week (i.e. 25 L/session).
A paper from the French Registry reported a better survival in patients treated with HDF [79] , with HR for all-cause mortality of 0.77 (95% CI 0.67-0.87) and HR of 0.66 (95% CI 0.50-0.86) for cardiovascular mortality.
Very recently, an update of the DOPPS evaluated the association of HDF with mortality in countries where HDF is FIGURE 1: All-cause mortality and risk ratios in randomized controlled trials that compared HD and HDF. [36] No difference No difference Mostovaya et al. [39] Reduced in HDF Reduced in HDF Nistor et al. [37] Reduced in HDF No difference Peters et al. [76] Reduced in HDF Reduced in HDF available in a 'real-world' clinical setting [80] . This paper included 8567 patients from seven European countries of DOPPS Phases 4-5 (2009-15) and with a dialysis vintage >90 days. HDF was the treatment of choice for 2012 (23%) patients; about half had replacement of fluid volume >20 L. Adjusted Cox regression was used to estimate the association between HDF (both overall and high-volume) and mortality (versus HD) . Surprisingly, the adjusted HR for all-cause mortality was 1.14 (95% CI 1.00-1.29) for HDF versus non-HDF and 1.08 (0.92-1.28) for HDF >20 L versus non-HDF, while the adjusted HR for cardiovascular and infection-related mortality was 1.20 (1.01-1.43) and 1.14 (0.83-1.56), respectively. A recent study performed in 64 Spanish Fresenius Medical Care clinics [81] reported a significant 24% reduction in all-cause mortality with HDF compared with hf-HD in 1012 propensity-score-matched patients, drawn from a total cohort of 3075 incident patients. This analysis of current HDF practices did not support the notion that HDF is a superior treatment in comparison with HD, even by focusing on HDF with the highest convection volumes, albeit a large majority of randomized and non-randomized clinical trials report an improved outcome associated with highconvective-volume HDF in comparison with HD. Given these contrasting results, the possible benefits of HDF on patient survival still requires validations.
S A F E T Y A N D C O S T
With respect to lf-HD and hf-HD, the main points of concerns of ol-HDF during the last years were safety and extra costs. Since ol-HDF is characterized by the infusion of large volumes of replacement fluid into the blood, the question arises whether ol-HDF does not increase the risk of infection. The five randomized studies were not specifically designed to study safety [34, 35, 40, 59, 60] . Overall, ol-HDF appeared very safe; the ESHOL trial even reported that infection-related mortality was 55% lower in HDF in comparison with HD [35] , although these findings were not confirmed by the other four trials. Until now, no study reported safety concerns related to the use of HDF.
The cost of HDF has decreased in recent years and, compared with hf-HD, HDF appears to be a cost-effective treatment for patients on dialysis [82] .
D I S C U S S I O N
At present, $18% ($70 000) of all dialysis patients in Europe receive online HDF, with substantially lower rates in Japan (8%; $35 000 patients) and no use in the USA. This large variation across countries is in part due to differences in regulatory approval for online production of replacement fluid and other technique-related issues (relative complexity and remaining cost and safety concerns) [80] . More importantly, after >40 years since the first clinical experience, the available evidence is still considered not strong enough to demonstrate that HDF provides better outcomes compared with HD.
Only one [35] out of the five recent randomized trials [34, 35, 40, 59, 60] -including the three specifically designed to test mortality as a primary endpoint [35, 59, 60] -showed a better survival in patients treated with ol-HDF in comparison with HD.
On the basis of observational studies [64, 73, 74, 70] , post hoc analyses of randomized trials [59, 60] and meta-analyses [39, 76] , some evidences suggest that high-convective-volume HDF could provide better patient outcomes, although other studies [72, 80] including a randomized trial [40] and a metaanalysis [37] do not support this effect.
Convective treatments showed a better intradialytic vascular stability in three randomized controlled trials [34, 35, 40] , including two that were specifically designed to test this endpoint [34, 40] . This was confirmed by the meta-analysis of Wang et al. [36] ; nevertheless, it is still a matter of discussion whether these findings are peculiar of the HDF technique or just related to the Donnan factor and to a small cold effect of the reinfusate.
Many studies [35, 60, 76, 78, 83] suggest the existence of a dose-response relationship between convective volume and mortality in HDF, but as of today, only secondary analyses and some observational trials support this suggestive and sensible hypothesis.
Why, after all this time, is there still no strong evidence demonstrating the superiority of HDF in comparison with hf-HD as theoretically expected?
It is always difficult to demonstrate the positive effect of survival of a single therapeutic approach in a population with so many comorbidities. This is why the majority of trials in dialysis patients are negative or inconclusive. Moreover, the characteristics of the dialysis filters have improved, especially in recent years. Today a better anticoagulation therapy allows for maintaining the performance of the dialyser until the end of the session. Different design of filters is associated with higher level of backfiltration, thus reducing the difference in convective volumes with respect to HDF. Finally, we cannot exclude that possibly we are at the high-end of the performance possibilities of the 4-h, three times a week, extra-corporeal dialysis, and today we can eventually expect only marginal improvements from any new therapeutic approach.
The fact that the European Dialysis group received a grant from European Community to develop the CONVINCE trial [84] is an implicit acknowledgement that the current body of evidence is inconclusive. However, this study is just comparing the clinical effect of two different levels of convective volumes, without considering the hf-HD as a comparator group, and this, in our view, is an important limitation. In our opinion, the design of a new trial should foresee two phases: the first one for selecting the patients unable to reach a convective volume >21 L; these patients should be randomized to continue with HDF or to be switched to HD. The patients who are able to reach a convective volume >21 L should be randomized to two levels of convective volumes: HDF with a convective volume >21 L and HDF with a convective volume <21 L in comparison with the patients of the same group randomized to HD.
C O N C L U S I O N
In conclusion, according to evidence-based medicine, there is a need for a well-designed clinical trial comparing high-or moderate-convection-volume HDF versus hf-HD, to clearly prove a clinical superiority of HDF, including the effect of different infusion volumes, on patient outcomes.
We look forward to the results of future trials evaluating the effect of different convective volumes of HDF versus high-flux HD on survival.
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